Rapid Micro Biosystems to Participate in the Stifel 2024 Healthcare Conference
Rapid Micro Biosystems (Nasdaq: RPID) announced its participation in the Stifel 2024 Healthcare Conference. President and CEO Rob Spignesi and CFO Sean Wirtjes will engage in a 30-minute Q&A session with the host analyst on Monday, November 18, 2024 at 11:30 a.m. Eastern Time. The company, which provides automation solutions for healthcare product manufacturing, will make the session available via live webcast on their investor relations website, with replay access available after the event.
Rapid Micro Biosystems (Nasdaq: RPID) ha annunciato la sua partecipazione alla Stifel 2024 Healthcare Conference. Il presidente e CEO Rob Spignesi e il CFO Sean Wirtjes parteciperanno a una sessione di domande e risposte di 30 minuti con l'analista ospitante lunedì 18 novembre 2024 alle 11:30 ora orientale. L'azienda, che fornisce soluzioni di automazione per la produzione di prodotti sanitari, renderà disponibile la sessione tramite webcast dal vivo sul proprio sito web per le relazioni con gli investitori, con accesso alla registrazione disponibile dopo l'evento.
Rapid Micro Biosystems (Nasdaq: RPID) anunció su participación en la Stifel 2024 Healthcare Conference. El presidente y CEO Rob Spignesi y el CFO Sean Wirtjes participarán en una sesión de preguntas y respuestas de 30 minutos con el analista anfitrión el lunes 18 de noviembre de 2024 a las 11:30 a.m. hora del este. La empresa, que ofrece soluciones de automatización para la fabricación de productos de atención médica, hará que la sesión esté disponible a través de una transmisión en vivo en su sitio web de relaciones con inversores, con acceso a la repetición disponible después del evento.
Rapid Micro Biosystems (Nasdaq: RPID)는 Stifel 2024 Healthcare Conference에 참여한다고 발표했습니다. 사장兼 CEO Rob Spignesi와 CFO Sean Wirtjes는 2024년 11월 18일 월요일 오전 11:30 동부 표준시 기준으로 진행하는 주최 애널리스트와의 30분간의 Q&A 세션에 참여합니다. 의료 제품 제조를 위한 자동화 솔루션을 제공하는 이 회사는 투자자 관계 웹사이트를 통해 생중계 세션을 제공하며, 이벤트 후에는 재생 접근이 가능합니다.
Rapid Micro Biosystems (Nasdaq: RPID) a annoncé sa participation à la Stifel 2024 Healthcare Conference. Le président et CEO Rob Spignesi ainsi que le CFO Sean Wirtjes participeront à une session de questions-réponses de 30 minutes avec l'analyste hôte lundi 18 novembre 2024 à 11h30, heure de l'Est. L'entreprise, qui propose des solutions d'automatisation pour la fabrication de produits de santé, rendra la session disponible via un webcast en direct sur son site internet dédié aux relations investisseurs, avec un accès à la rediffusion après l'événement.
Rapid Micro Biosystems (Nasdaq: RPID) gab die Teilnahme an der Stifel 2024 Healthcare Conference bekannt. Präsident und CEO Rob Spignesi und CFO Sean Wirtjes werden am Montag, den 18. November 2024 um 11:30 Uhr Eastern Time in einer 30-minütigen Q&A-Sitzung mit dem gastgebenden Analysten teilnehmen. Das Unternehmen, das Automatisierungslösungen für die Herstellung von Gesundheitsprodukten anbietet, wird die Sitzung über einen Livestream auf seiner Website für Investor Relations verfügbar machen, mit Zugriff auf die Wiederholung nach der Veranstaltung.
- None.
- None.
LEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2024 Healthcare Conference.
Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a 30-minute question-and-answer session with the host analyst on Monday, November 18, 2024 at 11:30 a.m. Eastern Time.
A live webcast will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.
FAQ
When is Rapid Micro Biosystems (RPID) presenting at the Stifel 2024 Healthcare Conference?
How can I watch Rapid Micro Biosystems' (RPID) Stifel Conference presentation?
Who will represent Rapid Micro Biosystems (RPID) at the Stifel 2024 Healthcare Conference?
